1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsLupus Research Program is sponsored by Department of the Army -- USAMRAA (Congressionally Directed Medical Research Programs). Supports research into lupus. The CDMRP aims to fund high-impact, high-risk, and high-gain projects.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Lupus Research Program, Congressionally Directed Medical Research Programs You are using an outdated browser. Please upgrade your browser to improve your experience. U.S. Department of War organization.
Due to routine system maintenance the CDMRP website will be unavailable from COB 24 April - 27 April COB.
DEPARTMENT OF WAR - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS Transforming Health Care through Innovative and Impactful Research Vision – To cure lupus through partnership of scientists, clinicians and persons affected by lupus Mission – Fund research to understand, prevent, and diagnose lupus and to improve treatments and quality of life of patients, including Service Members and their Families, Veterans and the general public.
» Click on Image to View Program Summary The Lupus Research Program (LRP) was first funded in FY17 to support innovative and impactful research that addresses significant issues and gaps in lupus. Lupus is a heterogeneous autoimmune disease that is difficult to diagnose and treat. There is currently no test available to diagnose lupus and it may take months or years for a person to be correctly diagnosed.
Because lupus attacks healthy cells and tissues in many parts of the body, patients can experience a wide range of symptoms such as fatigue, joint pain, skin lesions, and headaches. Lupus can also cause inflammation in the kidneys, brain, blood vessels, lungs, and heart which can result in serious complications including organ damage. Lupus patients require a multidisciplinary team of healthcare specialists depending on their symptoms.
Treatment options for lupus are highly dependent on an individual patient's symptoms. Some of the most commonly used drugs to treat lupus include Nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and immunosuppressants.
Long-term use of these treatments can result in serious side-effects including kidney problems, stomach bleeding, liver damage, increased risk of infection, decreased fertility, and increased risk of cancer. Better treatment options are a critical need for lupus patients.
Summary of FISCAL YEAR 2017 Stakeholders Meeting Connecting LRP Applicants with Other Funding Organizations The LRP is committed to leveraging efforts with other funding organizations to accelerate progress in lupus research.
At the time of funding notifications, the LRP will inform highly-rated, unfunded applicants about opportunities to provide their LRP applications and peer review summary statements to non-governmental funders, who will determine the specific criteria for funding consideration. The LRP will collaborate with partner organizations and consumer advocacy groups currently involved with the LRP.
Other organizations that would like to be connected with unfunded LRP applicants may send an email to dha. detrick. cdmrp.
mbx. public-affairs@health. mil .
By connecting excellent applicants with other funding organizations, the LRP is further advancing lupus research and supporting the lupus community.
Congressional Appropriations Recent Applications Recommended for Funding FY24 Peer Review Participants Lupus Research Program Annual Report FY24 LRP Recommended for Funding List Devyn Mitchell: Staying Involved in Her Own Lupus Journey Aim2 Couples with Ube2i for Repression of Interferon Signatures in Systemic Lupus Erythematosus Effects of ITGAM Genetic Variation on Mac-1-Mediated Functions of B-Cells Multi-Ancestral Genomic Approach to SLE-Precision Medicine The LRP Presents the Fiscal Year 2021 Transformative Vision Award Recipient The LRP Presents the Fiscal Year 2021 Impact Award Recipients The LRP Presents the Fiscal Year 2021 Idea Award Recipients Summary of FISCAL YEAR 2017 Stakeholders Meeting Matt Bellina: "ALS is a worthy adversary, but each day I am hopeful."
Improving the Effective Bioavailability of ALS Therapeutics Click here to provide feedback/comments to the LRP Last updated Friday, July 31, 2026
According to the current listing, eligibility includes: Open to any eligible entity including universities, nonprofits, and businesses. Confirm the full requirements in the official notice before applying.
Lupus Research Program is funded by Department of the Army -- USAMRAA (Congressionally Directed Medical Research Programs). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
FY26 DoD Vision Research Program Translational Research Award (TRA) is sponsored by Department of the Army -- USAMRAA (Congressionally Directed Medical Research Programs). This award funds translational vision research that takes a promising discovery toward actionable outcomes like new drugs, devices, or clinical practice guidelines that are ready for definitive clinical testing.
Rare Cancers Research Program (RCRP) Idea Development Award is sponsored by Department of the Army -- USAMRAA (Congressionally Directed Medical Research Programs). This award supports innovative, early-stage research projects on rare cancers, defined as those affecting six or fewer persons per 100,000 per year in the United States. The research should have a high potential impact on rare cancer outcomes and the patient community.
The memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articleAfter SBIR reauthorization, the U.S. Army released five new small-business topics under Army FUZE — Ka-Band metamaterial radar, a Li-ion 6T battery open topic, in-transit-visibility blockchain, modular UAS payloads, and the xTech|Phantum prize competition. Awards run from $150K to $300K per Phase I. But the bigger story is the Army's shift from funding parts to funding whole systems. Here is what each topic funds and how to compete.
Read articleDARPA BTO pre-released four FY26 SBIR/STTR topics on April 30, 2026, with proposals due June 3. Two topics — SWiFT and EXPOSITION — offer Direct-to-Phase-II awards up to $1.5M, bypassing the standard Phase I gate. Here is what each topic is actually solving, why the DP2 structure matters, and how small biotech, surgical robotics, and battlefield-medicine teams should decide whether to compete.
Read article